FREE CASE EVALUATION

*Phone:
  

* Required

Colorado Judicial Institute

Results

$5,350,000
Jury awards a Burg Simpson client $5.35 million for Bad Faith Breach of Insurance Contract.


$1,300,000
Jury award to Englewood company to total more than $1 million for breach of fiduciary duties in Shareholder Class Action Case.


$690,000,000
Global settlement with Eli Lilly and Company regarding its product Zyprexa negotiated by a plaintiffs' attorney group including members of Burg Simpson.


$5,800,000
Hines, et al, vs. Cody Gas Company, et al: verdict for injuries, damages, losses from gas explosion.


CLICK HERE FOR MORE INFORMATION

Our Offices

COLORADO OFFICE
- Headquarters

40 Inverness Drive East
Denver, CO 80112
Phone: 303.792.5595
Fax: 303.708.0527

 

WYOMING OFFICE
Phone: 307.527.7891
Fax: 307.527.7897

 

OHIO OFFICE
Phone: 513.852.5600
Fax: 513.852.5611

 

ARIZONA OFFICE
Phone: 602.508.6040

 

Home > Defective Drugs > Ortho Evra

Ortho Evra Claims Attorneys

Burg Simpson is at the forefront of the Ortho Evra litigation with multiple attorneys leading the litigation and discovery efforts.

  • Michael S. Burg, Burg Simpson founder and President, and Janet G. Abaray, Burg Simpson shareholder, have been appointed as co-lead counsel for all cases in Federal Court pending in the national Multidistrict Litigation.
  • Seth A. Katz, Burg Simpson shareholder, is one of the leaders of the Discovery Committee.  Mr. Katz is also at the forefront of the litigation in retrieving data from Johnson & Johnson’s databases, is leading a small group of lawyers in obtaining necessary evidence from third parties, and also serves on the Science and Expert Committee.  Mr. Katz was also elected as Co-Chair of the Ortho Evra American Association for Justice Litigation Group.  
  • John M. Restaino, D.P.M., J.D., Burg Simpson shareholder, is the Co-chair of the Science Committee.

Johnson & Johnson Altered Birth-Control Patch Data to Hide Risks

Click to view our video about "Ortho Evra Birth Control Patch"

"Drug Makers Near Old Goal: A Legal Shield"
– By Gardiner Harris and Alex Berenson, The New York Times

In April 2002, Johnson & Johnson introduced the Ortho Evra Birth Control Patch, which it promoted as being more convenient then the Pill due to its once weekly application for three consecutive weeks.  Unlike oral birth control, which undergoes first-pass metabolism in the liver, the progestin and estrogen in the Patch are released directly into the bloodstream.  The Patch was marketed to consumers as providing the same safety profile and efficacy as the birth control pill in preventing pregnancy, but with more convenience than birth control pills because it is worn on the skin for three consecutive weeks, with the fourth week being “Patch free.”  The aggressive marketing campaign, often describing Ortho Evra as “the Pill in a Bandaid,” resulted in sales of more than $424 million in 2005, based on 9.3 million prescriptions.

However, in November 2005, Johnson & Johnson revised its labeling for Ortho Evra, disclosing for the first time that the Patch exposed women to 60% more estrogen than a 35 microgram birth control pill.  Because higher estrogen levels are known to increase the risk of blood clots, which can cause deep vein thrombosis, pulmonary embolism, as well as heart attacks, strokes and even death, the revised label proves that the Patch poses far more danger to women than the Pill.  In fact, this increased exposure to estrogen makes the Patch comparable to the high-dose estrogen forms of the Pill that the FDA required to be removed from the market in 1988.

On September 20, 2006, Johnson & Johnson once again changed the Ortho Evra label and admitted in its revised product labeling that women on the Patch may be at more than twice the risk of developing blood clots in the lungs and legs as women using 35 microgram birth control pills.  The data indicating a doubling of the risk of serious blood clots arose from a study sponsored by Johnson & Johnson. 

In 2004, about a dozen women, mostly in their teens and early 20's, died from blood clots believed to be related to their use of Ortho Evra. Dozens more survived strokes and other blood clot related events. The first death known to be associated with Ortho Evra occurred in April 2005, when an 18-year old Manhattan woman collapsed and died in a New York subway station.

Many executives of Ortho-McNeil have already been deposed and about five million pages of documents have been produced. Discovery to date reveals that Ortho-McNeil's own studies documented the problems and that one study was suppressed because its outcome and conclusion was not favorable to Ortho-McNeil.

View our Ortho Evra brochure for more information.

If you believe you have a claim because you used Ortho Evra, please call or email us today for a free consultation. At Burg Simpson Eldredge Hersh & Jardine, P.C., our Colorado and Ohio attorneys represent people who have suffered injuries because of Ortho Evra.

Return to the Defective Drugs Section

Contact Us

1-888-895-2080

HOME WHY BURG SIMPSON ATTORNEYS OFFICES PUBLICATIONS NEWS PRESS & EVENTS COMMUNITY CONTACT US
COLORADO
WYOMING
OHIO
ARIZONA